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THE PREVALENCE AND SEVERITY OF FATIGUE IN LONG-TERM SUR- 
VIVORS OF ALLOGENEIC STEM CELL TRANSPLANTATION: A PRELIMI- 
NARY ANALYSIS 
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Bi*wdz~gham, United Kklgdom; 2. Lomlo~z Health Sciences Centre and 
the [hffversity of Weste~vz Ontario, TovoJzto, ON, C?mada; 3. Psycoso- 
ckd Oncology and Palliative Care Program~Princess Margaret Hospital 
a,d the Umversity of Toronto, Toronto, ON, Ca,ada; 4. P'dvzce.vs Mar- 
garet Hospital/U, iversity HeAlth Network and the Umvevsity ofToron- 
to, Toronto, ON, Canada. 
In allogeneic stem cell transplantation (alloSCT) populations, 
long-term fatigue is an important determinant of QOL that needs 
to be addressed. The  contribution of anemia to patients self- 
reported fatigue levels was examined. A questionnaire package was 
mailed to 290 recipients of blood or marrow allografts transplant- 
ed at our institution 1 to 7 years ago. The package included: 1) a 
100 mm Linear Analogue Self-Assessment (LASA) measure of 
energy, ability to perform daily activities, and overall QOL, 2) the 
anemia subscale of the FACT (FACT-An), which also includes 13 
items relating to fatigue (FACT-An fatigue subscale), and 3) a 
request for their most recent hemoglobin (Hb) level. An interim 
analysis was performed after 123 completed surveys (42%) had 
been returned. A total of 64% of the sample reported at least a 
mild level of fatigue, with 35 % reporting moderate to severe levels 
of fatigue on the FACT-An fatigue subscale. The FACT-An 
fatigue subscale scores were also standardized on a 1-100 scale 
(100 = no fatigue) and then compared to scores reported in studies 
of anemic cancer patients and healthy US individuals (1, 2). The 
mean score observed in our sample (63.3) was higher than the 
mean score observed in anemic cancer patients (56.7), but lower 
than the mean score obsmwed in healthy people (85.0). A total of 
26% of the sample met the criterion for anemia (Hb < 130 g/L for 
men and < 120 g/L for women). No significant correlations were 
found between Hb level and any of the fatigue measures. Other 
potential factors contributing to {:atigue were also examined. Sub- 
jects who were > 44 years old (median age) reported a higher level 
of fatigue than younger subjects on the LASA (energy level and 
daily activities) and the FACT-An fatigue subscale (p < 0.022). 
Level of fatigue was not related to the following potential risk fac- 
tors: gender, diagnosis, related vs. unrelated onor, GVHD, and 
time after SCT. Our findings suggest hat fatigue is a significant 
syanptom for the majority of long-term smwivors of alloSCT that 
appears to persist for years. However, anemia may not be a pri- 
mal T contributor to patients experience of fatigue. 1. Littlewood 
TJ et al. J Clin Oncol 2001; 19:2865-2874. 2. Nortier JWR et 
al.(abstract) Eur J Cancer 200i; 37:$35i (Supported by an unre- 
stricted grant from Ortho Biotech Canada). 
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POST-TRAUMATIC GROWTH: A LATE EFFECT OF STEM CELL 
TRANSPLANTATION 
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Stem cell transplantation (SCq) prolongs life for many people 
and offers a cure for some. However, its late effects can signifi- 
cantly negatively impact the quality of life (QOL) of survivors. 
Often overlooked, positive quality of life outcomes are possible, as 
well, particularly in the area of psychological growth. A large, 
multi-center, cross-sectional study was conducted to characterize 
the QOL and quality of close relationships of long-term survivors 
of autologous and allogeneic SCT diagnosed with acute leukemia, 
chronic myelogenous leukemia, lymphoma, and breast cancer. 
Four hundred seventy seven survivors, 159 spouses, and 123 
healthy controls (matched on gender, age, marital stares, and edu- 
cation) were assessed as of June 2002. As part of this study, post 
traumatic growth was measured using the Post -Traumat ic  
Growth inventory (PTGI).  Survivors were mostly Caucasian 
(92 %), married (70%), of mean age 49 years (range = 21 - 77), and 
employed fulltime (51%). Mean years since transplant at assess- 
lnent was 6.9 (range = 1.8 - 22.6). Compared to spouses (M = 59.0) 
and controls (M = 57.8), smwivors reported more psychological 
growth (M = 66.4, p <.0001). In univariate analyses greater post- 
traumatic growth was associated with lower levels of education, 
and higher support group participation, as well as being female, 
having had an autologous transplant, having had less intensive 
prior therapy, and being diagnosed with breast cancer (all rela- 
tionships significant at p < .05) . Post-traumatic growth in sur- 
vivors was associated with greater use of certain coping strategies 
including positive reftaming (r = .33), emotional support (r = .35), 
instrumental support (r = .27), emotional processing (r = .27), and 
emotional expression (r = .21) (all values significant at p<.0001). In 
addition, psychological growth was associated with greater levels 
of spiritual well-being (r = .29, p < .0001). We conclude that psy- 
chological growth is possible post-transplant and further study of 
this positive late effect is warranted. 
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IN VIVO PURGING AND POST TRANSPLANT IMMUNOTHERAPY WITH 
RITUXIMAB PRODUCES DURABLE REMISSIONS IN PATIENTS WITH 
LOW GRADE AND MANTLE CELL LYMPHOMA 
Flim~, L ~;  Diehl, L.; Gray'err, E.; Carter-Brook&s, D.; Goody#h, A.; 
Loper, K.; JoTzes, R.ff.; Amb&der, R.F. Sidne~ Kilnmel Compvehelzsive 
Cancer Center atffohns HopteiJzs, Baltimore, MD. 
The efficacy of autologous tem cell transplantation for patients 
with lymphoma is complicated by residual disease remaining in 
the patient despite the high dose therapy and the re-introduction 
of neoplastic ells with the autologous graft. We are conducting 
trials of ritu~mab used during stem cell mobilization and as a post 
transplant adjuvant in an attempt o overcome both of these obsta- 
cles. Patients with NHL  received 375 mg/m 2 of rimximab day 1 of 
mobilization, followed by cyclophosphamide 2.5 gm/m 2 day 4, and 
either G-CSF or G CSF and GM-CSF starting" day 6 through 
subsequent stem cell collection. Later patients were CD34 select- 
ed if at least 5 X 10 c' CD 34 + cells/kg were collected. The prepar- 
ative regimen consisted of either Cy/TBI or Bu/Cy. The first 25 
patients received a single dose of ritnximab 375 mg/m 2 given post- 
transplant 7 days after plts reach 20,000. Subsequent patient 
received GM-CSF post-transplant with four weekly doses of ritux- 
imab. One hundred and twelve patients (75M:37F), median age 
52.5 (range 32-69)and 2 (range 1-7) prior therapies have started 
therapy. Diagnoses include 60 FCC, 24 mantle ceil, and 18 
SLL/CLL. At time of transplant, 37 patients were in CR, 72 in 
PR. Mobilization was successful in 89% of pts with a median 14.0 
x 106 CD+ 34 cells/kg. The median day ANC > 1000 was 12 (7- 
24) and unsupported platelet > 20, 000 was 9 (3-663). The purging 
results measured by lymphoma colony forming units and PCR 
before and after CD34 selection are displayed in the table. The 
median follow-up is 2 years. Kaplan-Meier estimates of the three 
year ~)verall and relapse flee survival are 91.4% [82.8%, 95.8%] 
and 84% [70.4%, 91.7%]respectively. Notable toxieities include 
increased incidence of cytopenias (predominantly neutropenia) 
. after engraftment and several ate infections ( aspergillus, atypical 
mycobacteriuin, pseudomonas). YVe conclude that rituximab used 
as an in vivo purging agent and post transplant adjuvant is well 
tolerated and produces durable remissions in patients with low 
grade and mantle cell NHL.  Evaluation of ilnmune reconstitution 
and late infections is ongoing. This approach will be tested in a 
randomized phase III intergroup trial in patients with diffuse large 
cell lymphoma. 
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